MDGL
Madrigal Pharmaceuticals, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
20.36
P/S
13.09
EV/EBITDA
-48.03
DCF Value
$3,107.85
FCF Yield
-1.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
94.1%
Operating Margin
-31.3%
Net Margin
-30.1%
ROE
-43.8%
ROA
-23.0%
ROIC
-31.6%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $321.1M | $-58.6M | $-2.57 |
| FY 2025 | $958.4M | $-288.3M | $-12.85 |
| Q3 2025 | $287.3M | $-114.2M | $-5.08 |
| Q2 2025 | $212.8M | $-42.3M | $-1.90 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
-1.01
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.